Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 30;2018(1):382-389.
doi: 10.1182/asheducation-2018.1.382.

Autoimmune hemolytic anemia

Anita Hill  1 , Quentin A Hill  1
Affiliations
Review

Autoimmune hemolytic anemia

Anita Hill et al. Hematology Am Soc Hematol Educ Program. .

Abstract

The diagnosis of autoimmune hemolytic anemia (AIHA) can be made with a stepwise approach that aims to identify laboratory and clinical evidence of hemolysis and then determine the immune nature of hemolysis with the direct anti-globulin test. Once alternative causes for these findings have been excluded, AIHA is established, and the clinician must search for secondary causes, as well as identify the type of AIHA. Rituximab is now the preferred second-line treatment for primary warm AIHA and first-line treatment for primary cold agglutinin disease (CAD), either as monotherapy or combined with bendamustine. Complement inhibitors have shown utility in stabilizing AIHA patients with acute severe hemolysis. Future prospects are discussed and include the C1s inhibitor BIVV009 (sutimlimab) that is now entering phase 3 studies for CAD.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: A.H. and Q.A.H. have received honoraria from Bioverativ.

Figures

Figure 1.
Figure 1.
Blood film appearances in patients with AIHA (both using May Grunwald Giemsa stain). (A) Spherocyte in a patient with warm AIHA (original magnification, ×100). (B) Red cell agglutination in a patient with cold agglutinin disease (×40).
Figure 2.
Figure 2.
Diagnostic pathway for AIHA. DAggT, direct agglutination test; DIIHA, drug-induced immune hemolytic anemia; HA, hemolytic anemia; HDN, hemolytic disease of the newborn; HTR, hemolytic transfusion reaction; PLS, passenger lymphocyte syndrome; RT, room temperature. *The final diagnosis of CHAD or mixed AIHA is based on the overall clinical picture, including supportive serological findings. †For example, the thermal amplitude. **Saline-suspended red cells and patient’s serum at room temperature for 30 to 60 minutes. Adapted from Hill et al with permission.
See this image and copyright information in PMC

References

    1. Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases. Blood. 1987;69(3):820-826. - PubMed
    1. Fattizzo B, Zaninoni A, Nesa F, et al. . Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias. Am J Hematol. 2015;90(8):E149-E151. - PubMed
    1. Berentsen S. How I manage patients with cold agglutinin disease. Br J Haematol. 2018;181(3):320-330. - PubMed
    1. Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A; British Society for Haematology Guidelines. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017;177(2):208-220. - PubMed
    1. Molica S, Polliack A. Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy. Leuk Res. 2016;50:31-36. - PubMed

MeSH terms